Table 4.
Variable Selection of Regression Model for Human Immunodeficiency Virus (HlV)–Infected Patients
| ICA |
CCA |
|||||
|---|---|---|---|---|---|---|
| Model stage, variable | β ± SE | P | Adjusted R2 | β ± SE | P | Adjusted R2 |
| First stage | ||||||
| Demographics characteristic | 0.20 | 0.35 | ||||
| Age | 0.02 ± 0.01 | .15 | 0.02 ± <0.01 | .001 | ||
| BMI | –0.02 ± 0.02 | .39 | ±0.01 ± 0.01 | .95 | ||
| Sex | –0.03 ± 0.27 | .93 | –0.04 ± 0.13 | .73 | ||
| lipid-lowering drug use | 0.36 ± 0.19 | .06 | –0.07 ± 0.09 | .49 | ||
| Waist-to-hip ratio | 2.66 ± 1.39 | .06 | 1.75 ± 0.69 | .01 | ||
| Systolic blood pressure | 0.01 ± <0.01 | .11 | ±0.01 ± <0.01 | .23 | ||
| Laboratory value | <0.01 | 0.02 | ||||
| Non-HDL cholesterol | ±0.01 ± <0.01 | .45 | ±0.01 ± <0.01 | .25 | ||
| Triglycerides | ±0.01 ± <0.01 | .37 | ±0.01 ± <0.01 | .62 | ||
| Total cholesterol | ±0.01 ± <0.01 | .99 | ±0.01 ± <0.01 | .45 | ||
| HOMA-IR | 0.01 ± 0.02 | .56 | ±0.01 ± 0.01 | .56 | ||
| HIV infection measurement | 0.05 | <0.01 | ||||
| Absolute CD4 cell count | ±0.01 ± <0.01 | .44 | ±0.01 ± <0.01 | .67 | ||
| Nadir CD4 cell count | ±0.01 ± <0.01 | .86 | ±0.01 ± <0.01 | .78 | ||
| HIV duration | 0.03 ± 0.02 | .25 | ±0.01 ± 0.01 | .70 | ||
| NNRTI receipt duration | ±0.01 ± <0.01 | .05 | ±0.01 ± <0.01 | .19 | ||
| NRTI receipt duration | ±0.01 ± <0.01 | .05 | ±0.01 ± <0.01 | .20 | ||
| PI receipt duration | ±0.01 ± <0.01 | .03 | ±0.01 ± <0.01 | .40 | ||
| Biomarker | 0.10 | 0.03 | ||||
| sVCAM | ±0.01 ± <0.01 | .04 | ±0.01 ± <0.01 | .02 | ||
| MPO | ±0.01 ± <0.01 | .04 | ±0.01 ± <0.01 | .07 | ||
| vWF | ±0.01 ± <0.01 | .02 | ±0.01 ± <0.01 | .08 | ||
| TNF-α | ±0.01 ± <0.01 | .03 | ±0.01 ± <0.01 | .13 | ||
| sTNFR-I | ±0.01 ± <0.01 | .58 | ±0.01 ± <0.01 | .54 | ||
| sTNFR-II | ±0.01 ± <0.01 | .64 | ±0.01 ± <0.01 | .36 | ||
| ICAM-1 | ±0.01 ± <0.01 | .98 | ±0.01 ± <0.01 | .55 | ||
| hsCRP | ±0.01 ± <0.01 | .79 | ±0.01 ± <0.01 | .36 | ||
| IL-6 | ±0.01 ± <0.01 | .25 | ±0.01 ± <0.01 | .21 | ||
| Second stage | 0.23 | 0.40 | ||||
| Age | 0.03 ± 0.01 | .01 | 0.03 ± <0.01 | <.001 | ||
| Waist-to-hip ratio | 1.13 ± 1.31 | .40 | 1.39 ± 0.61 | .03 | ||
| Lipid-lowering drug use | 0.34 ± 0.18 | .07 | –0.07 ± 0.09 | .43 | ||
| NNRTI receipt duration | ±0.01 ± <0.01 | .81 | ... | |||
| NRTI receipt duration | ±0.01 ± <0.01 | .36 | ... | |||
| PI receipt duration | ±0.01 ± <0.01 | .33 | ... | |||
| sVCAM-1 | ±0.01 ± <0.01 | .02 | ±0.01 ± <0.01 | .34 | ||
| MPO | ±0.01 ± <0.01 | .06 | ±0.01 ± <0.01 | .04 | ||
| vWF | ±0.01 ± <0.01 | .27 | ±0.01 ± <0.01 | .22 | ||
| TNF-α | ±0.01 ± <0.01 | .05 | ±0.01 ± <0.01 | .16 | ||
| Final model | 0.27 | 0.38 | ||||
| Age | 0.03 ± <0.01 | <.001 | 0.03 ± <0.01 | <.001 | ||
| Waist-to-hip ratio | ... | 1.53 ± 0.59 | .01 | |||
| Lipid-lowering drug use | 0.30 ± 0.16 | .07 | ... | |||
| sVCAM-1 | ±0.01 ± <0.01 | .02 | ... | |||
| MPO | ±0.01 ± <0.01 | .03 | ... | |||
| TNF-α | ±0.01 ± <0.01 | .03 | ±0.01 ± <0.01 | .11 | ||
NOTE. BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CCA, common carotid artery; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP high-sensitivity C-reactive protein; ICA, internal carotid artery; IL, interleukin; IMT, intima-media thickness; MPO, myeloperoxidase; NNRTI, nonnucleoside analogue reverse-transcriptase inhibitor; NRTI, nucleoside analogue reverse-transcriptase inhibitor; PI, protease inhibitor; SE, standard error; sICAM-1, soluble intercellular adhesion molecule-1; sTNFR-I, soluble tumor necrosis factor-α receptor I; sTNFR-II, soluble tumor necrosis factor-α receptor II; sVCAM-1, soluble vascular cell adhesion molecule-1; TNF-α, tumor necrosis factor-α; vWF, von Willebrand factor.